Economics and risks of FDA’s Quality management maturity rating programme
European Pharmaceutical Review
SEPTEMBER 29, 2022
Can continuous manufacturing add shareholder value for pharmaceutical companies? The current state of the pharmaceutical market is characterised by an asymmetric information problem that introduces several market imperfections.
Let's personalize your content